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For both economic and ethical reasons, identiﬁcation of the optimal treatment for each individual patient
is a pressing concern, not only for the patients and their physician, but also health care payers and the
pharmaceutical industry. In the ﬁeld of osteoarthritis (OA) this is of particular relevance, due to the
heterogeneity of the disease and the very large number of affected individuals. There is a need to pair
the right patients with the right therapeutic modes of action. At present, the clinical trial failures in OA
may be a consequence of both bona ﬁde treatment failures and trial failures due to clinical design de-
ﬁciencies. Tools are needed for characterization and segregation of patients with OA. Key lessons may be
learned from advances with another form of arthritis, namely rheumatoid arthritis (RA).
Personalized health care (PHC) may be more advantageous for a number of speciﬁc indications which
are characterized by costly therapy, low response rates and signiﬁcant problems associated with trial and
error prescription, including the risk of serious side effects. We discuss the use of diagnostic practices
guiding RA treatment, which may serve as a source of key insights for diagnostic practices in OA. We
discuss the emerging concept of PHC, and outline the opportunities and current successes and failures
across the RA ﬁeld, as the OA ﬁeld collects further data to support the hypothesis. We attempt to outline a
possible path forward to assist patients, physicians, payers and the pharmaceutical industry in assuring
the ‘right’ patients are treated with the ‘right drug’ in OA. Finally we highlight methods for possible
segregation of OA patients that would allow identiﬁcation of patient subtypes, such as OA driven by
inﬂammation that may be ideally suited for PHC and for targeted therapies.
 2013 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
One of the most pressing needs in the health ﬁeld is to treat the
right patients with the right medicine. However, in light of the
current complete lack of structure modifying treatments for oste-
oarthritis (OA), the even more pressing issue is to identify the
optimal patient population in which to test a given treatment. For
patients with OA, non-surgical treatment consists notably of
physical therapy, lifestyle modiﬁcation, supportive devices, me-
dicinal pain relief, oral and injection drugs (e.g., non-steroidal anti-
inﬂammatory drugs). Once these treatments fail, surgery, such as
joint replacement, is the main option for the patients. Presently,
structure modiﬁcation trials are in part hindered by a combination
of slow and unpredictable disease progression, quantiﬁed by rela-
tively insensitive detection tools such as X-ray criteria. To enable
an optimal development program and later ensure that the rightM.A. Karsdal, Nordic Biosci-
nmark. Tel: 45-44-52-52-52.
arsdal).
s Research Society International. Ppatients are treated with the optimal intervention there is a need of
a method to segregate patients with different OA subtypes in order
to pair themwith an optimal mode of action. This may help redeem
the OA clinical trial area, and lessen the chances of false negative
conclusions.Which diseases are optimal candidates for personalized
health care (PHC) and what drives the need?
PHC has often been suggested as a solution1 to this complexity,
but the majority of examples of successful PHC are currently drawn
from oncology and, as such, reﬂect a relatively simplistic concept of
therapeutic stratiﬁcation based on the targeting of constitutively
activated pathways in an oligogenic model of disease. In contrast,
reportable successes for PHC in the ﬁeld of polygenic disease are
few. This poses the question of whether therapeutic areas and
speciﬁc diseases outside the ﬁeld of oncology can ultimately beneﬁt
from a tailored approach to therapy. It seems likely that certain
therapeutic areas may ultimately prove more amenable to the
application of PHC than others; these would be characterized byublished by Elsevier Ltd. All rights reserved.
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signiﬁcant disadvantages stemming from stochastic ‘trial and error’
prescribing that increases risk of adverse events and economic
burden due to exploratory prescriptions of high cost therapies.
Contrasting examples of the utility of a PHC paradigm are pro-
vided by osteoporosis and non-small-cell lung carcinoma (NSCLC).
In osteoporosis, the need for stratiﬁcation of patients is limited due
to the relatively benign side effect proﬁle and high response rates of
established therapies2e4, and the limited complexity of the disease
involving mainly one tissue, bone. Despite early reports linking the
commonly prescribed bisphosphonate therapies with stratiﬁed
responses in terms of bone mineralization5, novel clinical di-
agnostics have neither been extensively sought nor established, and
therapeutic practice remains solely based on prognostic investiga-
tion. In contrast, following the initial characterization of a number
of mutations that drive and maintain tumorgenesis6, diagnostic
practice for NSCLC has rapidly extended beyond classical pathology;
physicians now have an opportunity to target highly effective
therapies against signaling pathways activated by these mutations.
For the current discussion, we identiﬁed four major drivers of
PHC.
 Identiﬁcation of patients that are in greatest need of treatment.
 Identiﬁcation of the patients whom may respond optimally,
with the highest efﬁcacy and lowest safety concerns, to a given
treatment
 Development strategy for a selected subpopulation of patients.
 Efﬁcient use of health care resources.
Although PHCmight seem to be a highly attractive ‘magic bullet’
for patients, physicians, and payers, the interaction of several key
considerations dictates the ultimate level of attractiveness of a PHC
strategy. On the one hand, it is readily appreciated that the non-
targeted treatment of a particular group of patients may not pro-
vide a cost-beneﬁt-risk assessment that is adequately attractive
[Fig. 1(A)]. In addition, it is equally readily apparent that restricting
treatment to a diagnostically selected subpopulation with a high
likelihood of a response may signiﬁcantly and drastically improve
this assessment [Fig. 1(B)], whereas another selected treatmentFig. 1. A schematic representation of cost-beneﬁt assessment scenarios for different treatme
does not provide an attractive cost-beneﬁt assessment. (B) A subpopulation (1 & 2) treated
alternative therapeutic intervention (different from B) may be more suitable for a separate
unsuitable therapy results in adverse events and no efﬁcacy.more appropriate targets other patients [Fig. 1(C)], in contract to
the worst-case scenario in which only non-responders and Serious
adverse events (SAEs) are the result of treatment.
Given the central precept that treatment of non-responders
with a therapy associated with considerable side effects and costs
will only provide risk without beneﬁt to patients and waste scarce
health care resources, it would seem intuitive that treatments
delivering low response rates and a high potential for side effects
would have the most to gain from PHC. Identiﬁcation of non-
responders will be of particular concern if the adverse effects are
considered irreversible. Ethical and economic considerations
clearly drive the earlier identiﬁcation of such non-responders in
order to allow for selection of an alternative intervention.
The heterogeneity of the patient population e lessons learned
from rheumatoid arthritis (RA)
Experience with PHC in the context of RA provides an instruc-
tive example of the potential possibilities for OA. RA is a chronic
autoimmune disease characterized by poly-articular inﬂammation
resulting in massive tissue destruction in the affected synovial
joints. Due to fast progression of joint structural damage that may
lead to complete disability in less than 10 years, some patients need
to be treated aggressively7, and precise guidelines from European
league against rheumatology (EULAR) are provided for patient care
for both synthetic and biological interventions8e11. Methotrexate
therapy (MTX), often in combination with corticosteroids, is the
most commonly used Disease Modifying Anti-Rheumatic Drug
(DMARD) regimen in RA12,13. Upon inadequate response or intol-
erance to therapy, initiation of a biologic therapy is recom-
mended14. There are a growing number of approved biologic
therapies for RA. Given such a battery of diverse therapeutic op-
tions available to rheumatologists, it is not surprising that clinical
remission of RA, or at least low disease activity, is often the goal of
therapy15,16. However, the absolute performance of biological
therapies in randomized controlled studies in patients who have
failed initial DMARD therapy is very similar based on the stan-
dardized criteria established by the American College of Rheuma-
tology (ACR) for 20% (ACR20), 50% (ACR50) and 70% (ACR75)nts and different patient populations. (A) A treatment for a total group of patients that
with a targeted therapy may signiﬁcantly improve the cost-beneﬁt assessment. (C) An
and distinct patient population (4 & 5). (D) Treatment of the wrong patents with an
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45% for ACR50 and 10e25% for ACR7017e19. These data reveal a
heterogeneity of drug responses and point to a signiﬁcant and
remaining unmet need for alternative therapies for the substantial
number of patients who fall short of attaining remission or low
disease activity from current therapy15. Given the exposure of these
inadequately treated patients to the risk of adverse events, together
with a considerable societal economic burden of unremitting dis-
ease and cost of therapy, a PHC approach to the treatment of RA is
pursued aggressively. The success will require that the current
seemingly random stochastic approach to RA therapy needs to be
replaced by a mechanistic and predictive understanding of
response.
The heterogeneity of the patient population is heavily debated in
the OA; failures in clinical trials, have made it increasingly more
evident that OA is not one disease but has different phenotypes20.
Although the OA ﬁeld is still without efﬁcacious treatments to
validate this hypothesis, several subtypes have been identiﬁed that
may warrant different treatment strategies. Those subtypes
receiving the most attention currently include the following:
metabolic OA (including obesity)21,22, traumatic OA (including joint
malalignment)23, inﬂammation driven OA24 and subchondral bone
turnover driven OA phenotypes25. This may be illustrated sche-
matically as shown in Fig. 2. If a particular therapy works in a subset
of patientswith a speciﬁc disease phenotype, the response rateswill
be low in the absence of patient selection. Consequently, targeting a
particular disease phenotype with the etiologically appropriate
therapy would be expected to result in far higher response rates.
PHC in RA: current understanding of possible technological
advances
Presently there are few positive examples of PHC for RA. Sero-
positivity, the presence of autoantibodies to rheumatoid factor (RF)
or anticyclic citrullinated peptide (anti-CCP) observed in around
80% of patients, is an example of one type of biomarker with aFig. 2. Schematic overview to illustrate that different subtypes of patient exist that to some
cost-beneﬁt ratio may be achieved. (A) RA (and to an even larger extent OA) may consist
characterized. It is considered likely that each particular phenotype will respond different
phenotype with the consequence of an unmet medical need for a greater proportion of the
selected with a greater potential to respond to a speciﬁc therapy.modest ability to predict response to Rituximab26. Another
approach to the identiﬁcation of subgroups of therapeutic re-
sponders has been genetics based. RA has a strong, but complex
genetic etiology illustrated by the identiﬁcation of 31 risk loci in
seropositive RA, a very strong genetic risk factor HLA-DRB1, and the
group of alleles referred to as the shared epitope (SE). To date,
candidate and genome wide approaches to the discovery of
response genes have been taken for anti-Tumor necrosis factor
(TNF)17 and tocilizumab interventions. While associations have
been established, the predictive capability has so far been insufﬁ-
cient to have meaningful clinical application. Wang et al. reported
that polymorphisms identiﬁed in a genome wide association scan
(GWAS) each accounted for less than 2% of the variance observed
with change in DAS28 response to tocilizumab. Thirdly, the pro-
duction of antibodies against biologic therapies, such as to anti-TNF
antagonists, has also been associatedwithwaning of drug response.
Lastly, a multi-marker panel approach using 12 different markers is
being pursued by Crescendo29e31. While this may be predictive at
the group levels additional tailoring of the panel of markers and
algorithm may be needed to provide a meaningful result in the
clinical practice at the individual patient level. Models predicting
low disease activity (DAS28 < 3.2) at 52 weeks, utilizing clinical
data collected at 12 weeks, have been produced for etanercept,
etanercept with MTX, and certolizumab pegol32. These models
require validation in an independent dataset and analysis against a
non-anti-TNF therapy to determine if thesemodels are predictive of
response to a speciﬁc therapy33. Even for RA it is too optimistic to
suggest that the optimal marker combination and ﬁnal selection of
the right patient is present, exempliﬁed by the discussion in the RA
ﬁeld “Forget personalized medicine and focus on abating disease
activity”15.
For biomarkers to be utilized in PHC they need to be readily
measurable with an acceptable level of sensitivity and speciﬁcity,
accessible and reportable to physicians within a clinically action-
able timeframe. As suggested above, current standard practice for
RA at best provides an ACR50 response rate of 20e45% in aextent overlap, but only though targeting of the right subpopulation the most optimal
of many different molecular and clinical phenotypes that remain to be identiﬁed and
ly to therapies with differing modes of action. Treatment is not currently targeted by
rapeutic responses. (B) With patient selection through PHC, a given phenotype may be
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likely to respond to the treatment the response rate may be
increased and a subset of patients will not be exposed unneces-
sarily [Fig. 3(B)]. Thus an optimal strategy will both ensure a sig-
niﬁcant increase in response rates, but will also allow for exclusion
of those patients likely to have a serious treatment related side
effect.
A range of technologies may assist the implementation of PHC.
While such technologies must be technically robust, relatively
inexpensive, and easily accessible and simple to use, they are not
limited to the current generation of non-invasive biochemical
markers. A type of molecular marker has been developed that can
quantify the levels of tissue destruction associated with a pro-
gressing pathology34,35. In contrast to total proteinmeasurements of
established inﬂammatorybiomarkers, suchas interleukin (IL)-1, IL-6
and C-reactive protein (CRP), these new biomarkers rely on the
measurement of speciﬁc, circulating tissue protein fragments
generated by up-regulated, active proteolytic enzymes. As an
example, the major extracellular matrix (ECM) proteins of connec-
tive tissue in joints are type I, II and III collagen. Matrix metallo
protease (MMP)-mediated degradation of these collagens results
in the generation of the speciﬁc biomarkers, e.g., C1M, C2MandC3M
respectively36,38. Additional protein ﬁngerprints are generated by
distinct enzymatic processing of collagen or other ECM proteins
represented by the e.g., products like CTX-I, ICTP, CTX-II, C2C, ARGS
(aggrecan), FFGV (aggrecan), C4M (type IV collagen), C5M (type V
collagen) and C6M (type VI collagen)1,39. The measurement of
different degradation products of a protein may elucidate different
and frequently opposing metabolic mechanisms. This concept is
exempliﬁed by e.g., products of metabolism of type I collagen like:
PINP, CTX-I, C1Mand ICTPe each of these products provides distinct
and unique information. PINP is a pro-peptide released during
protein synthesis and can be measured as a surrogate biomarker of
both bone formation and ﬁbrogenesis40,41. CTX-I is a widely used
biomarker for Cathepsin K mediated destruction of type I collagen,
reﬂecting bone resorption42. ICTP is a triple cross-linked carboxy-
terminal telopeptide of type I collagen generated by MMP-activity,
but destroyed by the activity of other proteases43. ICTP is mainly
released from connective tissue turnover. Finally, C1M is also
released by the action of MMP’s from the helical domain of type IFig. 3. (A) Treatment of the entire patient population, without preselection of patients, resul
rate, thus drastically improving the cost-beneﬁt and beneﬁt-risk assessments. Importantly
treatment, but also those patients who should not be exposed to the drug. Thus, an optimal s
through exclusion of patients from the treatment pool for whom the therapy poses a serious
“half-man” being a non-responder as well as subject to an SAE.collagen. These different products of type I collagen provide
different and complementary information on tissue integrity and
turnover even though they in essence are measures of the same
protein, albeit in different ways.What does this mean for the OA ﬁeld?
The list of failures and limited successes in clinical development
for OA is growing, and includes among others, Inducible nitric oxide
synthase (iNOS), strontium ranelate, Calcitonin, MMP inhibitors,
Cathepsin K inhibitors and bisphosphonates44e47. These disap-
pointing results may in part be due to hypothesis failures but also a
result of applying these therapies to non-selected patient pop-
ulations. Figure 4 offers a very preliminary but possibly clinically
meaningful and clinically feasible strategy for selecting OA patients.
OA might be divided into at least three different subtypes based on
the most active joint tissue at a particular stage of disease (bone,
cartilage and inﬂamed synovium)or the tissuewith thepredominant
manifestations in particular patient populations. As examples,
Treatment 1may target early cartilage pathology such asmanifested
in traumaticOA,withhighprotease activities in thearticular cartilage
such as MMP and aggrecanase activities. Treatment 2 would target
both bone and cartilage involvement, such as manifested in post-
menopausal generalized OA. Treatment 3 may target late stage
inﬂammation drivenOA. Clearly these three different subtypes of OA
would require different interventions anddiagnostic algorithms, and
one treatment that may be successful in one patient populationmay
fail in another.
Based on even this simplistic subdivision of patients groups, the
following treatment scenarios might be suggested.
 Patient phenotype 1: Traumatic OA, in the early disease course
most likely involving a high level of protease activity destroying
the cartilage subsequent to cartilage injury. These patients
might beneﬁt from a protease inhibitor treatment.
 Patient phenotype 2: Generalized OA, with high turnover of
bone and progression of cartilage damage characterized by an
intimate relationship between bone and cartilage in the
pathogenesis of OA. These patients may beneﬁt from an anti-ting in 30% response rates. (B) Preselecting 50% of patients may result in a 60% response
, PHC is of beneﬁt for not only identifying those patients who will respond safely to
trategy will both ensure an enrichment of response rates, and lower adverse event rates
risk. Importantly, SAEs can and may also occur in selected patients, as illustrated by the
Fig. 5. The present ﬁgure illustrates key drivers of the disease and their speculated
impact on the rate of disease progression. These distinct drivers of disease may be
highly OA stage dependent and overlap to some extent. The length of the line is
considered the relative importance, as such the line is longer for hormonal than
autoimmunity driven OA disease, and consequently autoimmunity may lead to joint
failure faster than hormonal regulations. All cases of OA may be caused by a minor or
major joint trauma; however the rate of progression may be driven and accelerated by
different factors. These factors may describe different OA phenotypes, and these factors
may also be applied as tools for PHC allowing early segregation of patient as compared
to traditional clinical diagnosis of symptomatic OA. Note that this ﬁgure provides a
working hypothesis (and is hypothetical) as we do not know whether genetic factors
are more important leading to faster progression (shorter length of the line) than e.g.,
mechano-transduction.
Fig. 4. The drivers of OA may be divided into at least three different categories: bone,
cartilage and inﬂamed synovium. These may represent different disease subgroups;
alternatively they may represent the predominant tissue pathology during a particular
stage of disease. Optimal therapy may be considered the ability to detect and target
each of these stages or subgroups of disease.
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chondral bone turnover.
 Patient phenotype 3: Episodic subacute and acute inﬂammatory
events precipitating worsening in stages. Macrophages play a
role in this process48 and likely will yield pathways to inform
speciﬁc anti-inﬂammatory therapies for this phenotype or stage
of disease.
This approach underscores the need to better understand the
multiple pathways that result in the common end stage we refer to
as OA. While these delineations may overlap to some extent and be
dependent on the time and stage of disease, the scenarios represent
testable hypotheses that call for further research to validate and
reﬁne algorithms for clinically meaningful patient phenotyping.
Do different phenotypes in OA represent different
pathological stages and/or different phenotypes?
It is important to recognize that OA is far from a static disease,
and represents very distinct characteristics during the various
stages of disease progression, i.e., the above mentioned phenotypes
may vary over time. The different phenotypes of OA21 most likely
depend on many factors such as metabolic, traumatic, genetic and
lifestyle dependent factors. Currently we may understand that OA
may be triggered by amacro- or micro-traumatic injury to the joint,
where the trauma can be an acute accident or daily microinjury
respectively. Such events result in high turnover of the bone and
cartilage compartments, which eventually leads to symptomatic OA
and joint failure, as illustrated in Fig. 5.
It will be important to improve our ability to identify factors that
identify the various phenotypes of OA; to the extent to which we
can more precisely identify these phenotypes, the more capable we
will be at developing personalized treatments. Currently several
factors related to OA disease progression may be identiﬁed
including the following (as outlined in Fig. 5), which needs further
experimental evidence and independent validation: (1) Low grade
autoimmunity possibly plays a role in a subset of patients in whom
there is epitope spreading from the injured joint and activation of
the innate immune system49e51; (2) Inﬂammation, inwhich release
of factors such as cytokines andmatrikines act as pro-inﬂammatory
factors49,52; (3) Genetic, wherein speciﬁc Single nucleotide poly-
morphisms (SNPs) may predispose to fast progression through lossof function of key proteins53; (4) Hormonal, representing an
imbalance in the endocrine system that may result in loss of skel-
etal protections, as observed in some postmenopausal women54;
(5) Metabolic, in which an unhealthy phenotype, such as obesity,
may drive OA through adiopokines21; and (6) Mechano-
transduction, in which mechanical loading may drive a “wear and
tear” effect. Importantly, some factors may predispose at individual
stages to either slow or fast progression; these are discussed and
outlined in Table I. Of key importance, the risk factors and analysis
methods outlined in Table I, may optimally be used in combination
rather than stand alone technologies, in which imaging [X-ray and
magnetic resonance imaging (MRI)], standard demographic
description, genetic and novel biomarkers together provide value
to patients. Such combination of modalities, imaging, demographic
and serological biomarkers has in a few clinical settings been
shown to provide additional improvement in odds ratios for
identiﬁcation of i.e., progression55.
A few factors of relevance to the different type/stages of OA are
given attention. The release of citrullinated fragments of different
ECM proteins as well as intracellular proteins has been shown to act
as autoantigens. To date, one such fragment, VICM, has been
identiﬁed and shown to predict radiographic joint disease pro-
gression in a subset of patients56. Genetic factors may also be of
particular importance as GDF5 mutations57 have been shown to
predispose to a lack of repair potential, which may be of paramount
importance after traumatic injury. In addition, there are a long list
of genes that are related to cartilage and bone metabolism such as
Receptor activator of nuclear factor kappa-B ligand (RANK), RANK-
L, Sclerostin, Cathepsin K, V-ATPase, CLC-7, MMP-9 and -2, that may
inﬂuence the traumatic and high turnover stage of disease58,59.
Further, our current understanding of OA suggests that inﬂamma-
tion may be a driver of disease albeit not an initiator of disease, as
mutations in IL-1, predispose to inﬂammation and consequently
fast progression in OA24,60. This would be consistent with the
biology of IL-1 and IL-1 receptor in chondrocyte function and
cartilage degradation61. In parallel to RA where early radiographic
Table I
Potential biomarkers for clinical and molecular phenotyping of patients for PHC in OA
Phenotype Quantiﬁable measure in synovial ﬂuid, blood or urine Reference
Low grade autoimmunity Increase in speciﬁc autoantibodies [e.g., anti-CCP, anti-modiﬁed citrullinated vimentin (MCV)
antibodies, antibodies against citrullinated type I and II collagen fragments]
Increase in autoantigens [e.g., citrullinated and MMP degraded vimentin (VICM), citrullinated
ﬁbrinogen, Fibulin-4]
50,56,72e77
Auto-inﬂammation Local and systemic increase in matrikines from cartilage degradation and synovial
turnover [e.g., Hyaluron (HA), ﬁbronectin fragments]
78e88
Genetic SNPs in genes associated with joint tissue protection (e.g., GDF5, IL-1, DIO2, IL1RN, WNT pathway)
SNPs and dysregulation of bone speciﬁc proteins (e.g., RANK, RANK-L, Sclerostin,
Cathepsin K, V-ATPase, CLC-7, MMP-9 and -2)
57e59,89e91
Hormonal Estrogen loss (e.g., E2, FSH, Progesterone)
Increase in thyroid hormone (e.g., PTH)
21,92
Metabolic Increase in systemic levels of adipokines (e.g., leptin, resistin, adiponectin, visfatin) 93e97
Mechano-transduction Above normal levels of cartilage degradation fragments (e.g., cartilage oligomeric matrix
protein (COMP), dCOMP, CTX-II, C2M, C2C, AGNx1, ﬁbronectin)
Increased synovial ﬂuid proteolytical activity (e.g., MMP1, MMP3)
Bone sclerosis and turnover (e.g., alpha-CTX-I, sclerostin, RANK-L, osteocalcin)
82e85,98e101
Demographic Age, signiﬁcant trauma, obesity, altered gait, altered biomechanics
(varus or valgus deformity), and excessive loading on the affected joint
65,66
Imaging MRI assessment of the joint including; cartilage surface, damage/lesions, synovitis,
Bone morrow edema (BME), osteophytes and subchondral bone (shape and trabecular structure)
in addition to other advanced technologies
55,63,64
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concept is applied to OAwhere different imaging modalities clearly
may assist in delineating different phenotypes and progres-
sion55,63,64. These combined highlighted modalities, in addition to
the traditional risk factors; age, signiﬁcant trauma, obesity, altered
gait, altered biomechanics (for example, a varus or valgus defor-
mity), and excessive loading on the affected joint65,66, may be part
of a proposition for PHC in OA.
One relevant example of PHC in OA may be found in the recent
ﬁbroblast growth factor (FGF)-18 studies. In a retrospective analysis
of data from a clinical trial with Sprifermin (rhFGF18)67, a combi-
nation of two SNPs in the IL1RN gene could be indicative of disease
severity/progression as well as potential response to Sprifermin in
deﬁned genetic groups68. Four groups of patients were identiﬁed
and tested for a statistical association with change in cartilage
thickness/volume (asmeasuredbyMRI) andWOMACscores.Groups
of patients stratiﬁed for the SNPs rs9005 and rs315952 showed
better response to Sprifermin therapy in termsof cartilagevolume68.
This genetic stratiﬁcation may be combined with serological tech-
nologies or other biomarkers such as described in Table I to further
improve the prediction.
Which technological advances may facilitate the advent of
PHC for the OA ﬁeld?
TheOAﬁeld is somewhat behind theRAﬁeld, although also in the
RA ﬁeld stratiﬁed phenotype directed treatment is also still in
development This difference in the available toolbox, critical to the
success of PHC, is most likely due to the current lack of successful
intervention strategies in OA. This is further underscored by the
almost accepted postulation in the OA ﬁeld that novel treatments
may more readily be identiﬁed and developed by identiﬁcation of
the right subpopulation of OApatients. Consequently, this discussion
is reminiscent of the chicken and the egg discussion. However, with
the emerging BIPED categorization and stratiﬁcation of biochemical
markers in the OA ﬁeld69, tools are beginning to be identiﬁed that
may assist in the advent of PHC for OA. Different methodologies are
being classiﬁed as reﬂecting Burden of disease (B), Investigative (I),
Prognostic (P), Efﬁcacy of intervention (E), Diagnostic (D) and (S)
Safety69,70. Of most importance for PHC would be Prognostic
markers at baseline that could predict optimal responders and Safety
markers. Table I lists some of the genetic risk factors identiﬁed inGWAS studies, biochemical markers, and imaging markers which
may facilitate the establishment of a PHC paradigm in OA by helping
to deﬁne optimal patient populations for speciﬁc interventions.
We suggest that there needs to be a focused effort on PHC that
could be initiated in existing cohorts. PHC efforts could be groun-
ded in analyses of markers such as those listed in Table I, to identify
patients most likely to respond to a particular treatment. In addi-
tion, in other ﬁelds, marker panels are emerging for speciﬁc organ
toxicity, such as the acute kidney injury panel71, which is in direct
alignment with the suggestion of the “FDA critical path” that the
efﬁcacy marker of one pathology may be the safety marker of
another1. Such public efforts may assist in generating a better road-
map for drug development in the OA ﬁeld, by identiﬁcation of the
OA patient in whom safety indicators are optimized. Such efforts
should also provide quicker and safer decision making in drug
development that are of paramount importance for pharmaceutical
companies to commit the needed investments in later stage clinical
development. These efforts are expected to further lower the in-
vestment barrier, allowing more optimal clinical trial design for
critical POC studies allowing for trials with fewer patients and
shorter trial durations to reach an objective decision point. The best
biomarkers would improve success related to the following:
1. Identiﬁcation of fast progressors
2. Identiﬁcation of the optimal patients for a speciﬁc type of
intervention
3. Enablement of phase II and III studies with fewer patients
4. Decreasing cost of trials
5. Minimizing drug-related adverse events
6. Potentially providing early conﬁdence in mechanism of action
7. Surveillance for off-target effectsConclusion
In conclusion, experience to date suggests that most medicines
need to be developed to target speciﬁc subpopulations. We propose
that OA is a suitable candidate for the application of PHC. As novel
technologies and advanced clinical chemistry approaches, such as
proteinﬁngerprints or other robustmethodologies, become a reality,
the feasibility of PHC increases. The ever increasing prospect of PHC
offers hope for a better future for patients, physicians and payers.
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